Réf. :HematoStat.net ; 2 (6) : R48 Ram R, Grisariu S, Shargian-Alon L, Amit O, Bar-On Y, Stepensky P, et al. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years [...]

Réf. :HematoStat.net ; 2 (6) : R47 Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, et al. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 14 avr 2022;386(15):1421‑31. Résumé Dans cet essai de phase 1-2, [...]

Réf. :HematoStat.net ; 2 (6) : R46 Bachy E, Houot R, Feugier P, Bouabdallah K, Bouabdallah R, Virelizier EN, et al. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study. Blood. 14 avr 2022;139(15):2338‑46. Résumé : [...]

Réf. :HematoStat.net ; 2 (6) : R45 de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A, et al. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular [...]

Réf. :HematoStat.net ; 2 (3) : R44 Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, et al. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. [...]

Réf. :HematoStat.net ; 2 (3) : R43 Wu Y-J, Liu H, Zeng Q-Z, Liu Y, Wang J-W, Wang W-S, et al. All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. Blood. 20 janv 2022;139(3):333‑42. Résumé Cette étude [...]

Réf. :HematoStat.net ; 2 (3) : R42 Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 17 févr 2022;386(7):640‑54. Résumé Dans l’essai ZUMA-7, 359 patients [...]

Réf. :HematoStat.net ; 2 (3) : R41 Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 13 déc [...]

Réf. :HematoStat.net ; 2 (3) : R40 Gibson CJ, Kim HT, Zhao L, Murdock HM, Hambley B, Ogata A, et al. Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. J Clin Oncol. 10 janv 2022;40(2):189‑201. Résumé Dans le cadre d’une allogreffe, certains [...]

Réf. :HematoStat.net ; 2 (3) : R39 Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, et al. Polatuzumab Vedotin in Précédently Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 27 janv 2022;386(4):351‑63. Résumé L’étude POLARIX, essai de [...]